Addyi (Flibanserin) in Adults 65 and Older: Geriatric and Developmental Impact

What Flibanserin Is and How It Works

Flibanserin is a non-hormonal, centrally acting agent approved by the FDA in August 2015 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts as a 5-HT1A agonist and 5-HT2A antagonist, and as a dopamine D4 receptor partial agonist, modulating neurotransmitter activity in prefrontal circuits thought to regulate sexual motivation. [1]

The drug is taken as a single 100 mg oral tablet at bedtime. That bedtime-only restriction exists specifically because CNS depression, dizziness, and hypotension are pronounced in the hours immediately after dosing.

FDA-Approved Population vs. Geriatric Reality

The approved label is narrow. The three key Phase III trials (DAISY, VIOLET, and BEGONIA) collectively enrolled roughly 2,400 premenopausal women, with a mean age in the mid-to-late 30s. [2] Postmenopausal status itself was an exclusion criterion in all three studies. Adults 65 and older were not a target subgroup and represented a negligible fraction of trial participants, meaning no meaningful geriatric efficacy or safety data were generated during the clinical development program.

The FDA's prescribing information states plainly: "The safety and efficacy of ADDYI in postmenopausal women or in men have not been established." That sentence is clinically significant for any provider considering off-label use in a patient over 65.

Why Aging Changes the Pharmacology

Liver metabolism slows with age. Flibanserin is almost entirely cleared via CYP3A4 and CYP2C19 hepatic enzymes, and both pathways show reduced activity in older adults due to decreased hepatic blood flow and enzyme expression. [3] In a dedicated hepatic-impairment study, mild hepatic impairment (Child-Pugh A) already doubled flibanserin exposure. The drug is contraindicated in moderate and severe hepatic impairment regardless of age.

Renal clearance is a secondary route, and creatinine clearance declines roughly 1 mL/min per year after age 40. [4] No dose adjustments are formally specified for renal impairment alone, but the combined effect of declining hepatic and renal function in a 70-year-old creates a systemic exposure profile that is entirely extrapolated rather than measured in trials.

Pharmacokinetics in the Geriatric Patient

Age alters nearly every pharmacokinetic parameter that matters for flibanserin.

Distribution and Protein Binding

Flibanserin is approximately 98% protein-bound, primarily to albumin. Serum albumin falls with age, illness, and poor nutrition. Lower albumin means a higher free fraction of drug available at receptor sites, effectively raising active drug concentration without any change in the dose prescribed. [5] A 68-year-old woman with albumin of 3.2 g/dL receives a pharmacologically larger dose than a 35-year-old with albumin of 4.5 g/dL, even if both swallow an identical 100 mg tablet.

Volume of Distribution and Fat-to-Lean Ratio

Body composition shifts toward higher fat-to-lean ratios in older adults. Lipophilic drugs, which flibanserin is (log P approximately 2.4), tend to accumulate in adipose tissue, extending their half-life. Flibanserin's mean half-life is 11 hours in healthy young adults. [1] That number is likely longer in a geriatric patient, though no published trial has formally measured it in adults over 65.

CYP3A4 Inhibitor Interactions: A Specific Geriatric Hazard

The most serious pharmacokinetic interaction with flibanserin involves CYP3A4 inhibitors. Co-administration with fluconazole (a moderate-to-strong CYP3A4 and CYP2C19 inhibitor frequently prescribed in older women for recurrent vulvovaginal candidiasis) raised flibanserin AUC 7-fold in a dedicated drug-interaction study. [1] Ketoconazole increased AUC approximately 4.5-fold. Even diltiazem, a calcium-channel blocker commonly prescribed for rate control in atrial fibrillation (a disease whose prevalence exceeds 10% in adults over 65), raised flibanserin AUC roughly 2-fold. [6]

Older adults carry a higher prescription burden. A 2019 analysis published in JAMA Internal Medicine found that adults aged 65 to 79 filled a mean of 6.9 unique prescription medications annually. [7] Each additional CYP3A4-interactive drug compounds the exposure risk.

Safety Signals of Greatest Concern in Geriatric Patients

CNS Depression and Fall Risk

Flibanserin causes dose-dependent CNS depression. In the key trials, somnolence occurred in 11.4% of flibanserin-treated participants versus 3.4% on placebo, and dizziness in 11.4% versus 2.2%. [2] These rates were observed in healthy premenopausal women in their 30s. CNS sensitivity rises with age because of reductions in GABA receptor reserve, decreased cerebral blood flow, and the accumulative effect of polypharmacy.

Falls are the leading cause of injury-related death in adults 65 and older in the United States, accounting for more than 36,000 deaths annually according to the CDC. [8] Any agent that increases dizziness, sedation, or orthostatic hypotension carries an outsized danger in this population. The American Geriatrics Society Beers Criteria specifically flags centrally acting drugs with CNS depression as potentially inappropriate for older adults. While flibanserin is not currently listed by name in the 2023 Beers Criteria update, the mechanistic profile aligns closely with the criteria's flagged drug categories. [9]

Hypotension and Syncope

Flibanserin's vasodilatory effects are partly mediated through dopamine D4 receptor activity in vascular smooth muscle. Syncope was reported in 0.4% of patients in clinical trials, a rate that sounds small but represents a meaningful absolute risk in a frail older adult. [1] Orthostatic hypotension affects approximately 20% of community-dwelling adults over 70. [10] Combining a drug with hypotensive properties with a baseline condition of poor vascular autoregulation creates additive risk that no published trial has quantified in this age group.

Alcohol Interaction

The FDA mandates alcohol avoidance under the ADDYI REMS because co-ingestion produced severe hypotension and loss of consciousness in dedicated alcohol-interaction studies. In those studies, participants were young healthy adults. No equivalent study exists in older adults, but the interaction mechanisms are pharmacodynamic rather than pharmacokinetic, meaning age-related volume-of-distribution changes for alcohol (older adults reach higher blood alcohol concentrations per drink due to lower total body water) would plausibly worsen outcomes. [11]

Alcohol use in older adults is not uncommon. A 2020 survey reported that roughly 40% of adults aged 65 and older consumed alcohol in the preceding 30 days. [12] Abstinence requirements built into REMS programs are harder to guarantee in community-dwelling patients who may have daily wine with dinner as a longstanding routine.

Geriatric Polypharmacy and Drug-Drug Interactions

Polypharmacy amplifies every risk above.

Antihypertensives

Flibanserin lowers blood pressure. Adding it to a regimen that already includes an ACE inhibitor, ARB, beta-blocker, or calcium-channel blocker compounds the hypotensive effect. As noted above, diltiazem also inhibits CYP3A4, meaning it simultaneously raises flibanserin plasma concentrations and adds pharmacodynamic hypotension. [6]

Benzodiazepines and Sleep Aids

Benzodiazepines are prescribed at concerning rates in older adults despite longstanding Beers Criteria warnings. Any CNS depressant stacked with flibanserin's own sedation profile raises the probability of falls, respiratory depression in patients with sleep-disordered breathing, and next-day cognitive impairment.

Opioids and Gabapentinoids

Chronic pain is prevalent in older adults, and opioid or gabapentinoid co-prescription with a CNS depressant warrants explicit caution. The FDA's 2016 black-box warning on CNS depressant combinations with opioids is not specific to flibanserin, but the underlying pharmacodynamic rationale applies.

A Practical Prescribing Decision Framework for Older Women With HSDD

For a clinician evaluating an older woman (65+) presenting with decreased sexual desire, the following stepwise approach reflects the available evidence and geriatric pharmacology principles:

1. Confirm the diagnosis is acquired and generalized HSDD, not situational low desire or desire discrepancy between partners.
2. Screen for and address modifiable contributors: relationship conflict, depression, androgen deficiency, genitourinary syndrome of menopause (GSM), pain during intercourse, medication side effects (SSRIs are the most common iatrogenic cause).
3. Offer evidence-supported first-line options for postmenopausal women: local vaginal estrogen (lowest systemic exposure), ospemifene 60 mg daily for dyspareunia-associated desire reduction, or cognitive-behavioral sex therapy.
4. If HSDD persists after step 3 and the patient is still biologically premenopausal at age 65 (rare but possible in late perimenopause), review the full medication list for CYP3A4 inhibitors and CNS depressants before considering flibanserin. Obtain baseline orthostatic blood pressures.
5. If any CNS depressant, CYP3A4 inhibitor, or clinically significant hepatic impairment is present, do not prescribe flibanserin regardless of menopausal status.

This framework is not an official guideline but reflects a synthesis of FDA labeling, AGS Beers Criteria principles, and the pharmacokinetic data reviewed above.

Regulatory and REMS Considerations

The FDA approved flibanserin under a Risk Evaluation and Mitigation Strategy (REMS) titled the ADDYI REMS. Under this program, prescribers must be certified, pharmacies must be enrolled, and patients must be counseled specifically about the alcohol interaction and CNS depression risk. [13]

The REMS does not include a specific geriatric use restriction, which creates a potential gap. Prescribers can technically enroll and certify regardless of whether they are planning to prescribe within or outside the labeled indication. Off-label use in postmenopausal women over 65 is therefore not blocked by the REMS mechanism itself. The burden falls on the individual clinician.

The FDA's own review documentation from the 2015 Advisory Committee meeting noted that the benefit-to-risk assessment was marginal even in the approved premenopausal population, with the committee voting 18 to 6 in favor of approval only after Sprout Pharmaceuticals agreed to the REMS. [13] That marginal benefit calculation becomes more concerning when applied to a population with no efficacy data and substantially elevated risk.

What the Evidence Actually Shows for Sexual Dysfunction in Older Women

HSDD Prevalence in Older Adults

HSDD prevalence in postmenopausal women is estimated at 10% to 14% by most epidemiological surveys, though measurement varies widely by instrument and how distress is defined. [14] The condition is real, causes meaningful quality-of-life impairment, and deserves serious clinical attention. The absence of a safe pharmacological option does not mean the problem should be dismissed.

Alternatives With Actual Evidence in This Population

Ospemifene, a selective estrogen receptor modulator (SERM), is FDA-approved for moderate-to-severe dyspareunia and vulvovaginal atrophy in postmenopausal women. A 52-week safety extension study (N=426) confirmed sustained efficacy and tolerability with no new safety signals. [15] Dyspareunia is frequently intertwined with low desire in older women, and treating the pain component often resolves the desire complaint.

Local vaginal estrogen (creams, tablets, rings) at low doses produces minimal systemic absorption and is endorsed by the Menopause Society (formerly NAMS) for genitourinary syndrome of menopause in most postmenopausal women, including breast cancer survivors in some circumstances. [16]

Testosterone therapy for HSDD in postmenopausal women has evidence from the Intrinsa trials and the 2014 Endocrine Society position statement, which stated: "We recommend against the generalized use of testosterone by women but support its use for HSDD after a thorough evaluation." [17] Off-label transdermal testosterone at physiological doses remains an option when appropriately monitored, with a pharmacological safety profile considerably more favorable than flibanserin in older adults.

Sex Therapy and Psychosocial Interventions

A 2019 Cochrane systematic review of psychological interventions for female sexual dysfunction found moderate-certainty evidence supporting mindfulness-based therapy and cognitive-behavioral therapy for sexual desire concerns. [18] These approaches carry no pharmacokinetic risk, no drug interactions, and no hypotensive adverse effects. For the 65-plus population, they should be offered before, or alongside, any pharmacological consideration.

Clinical Bottom Line

Flibanserin was developed for, studied in, and approved for premenopausal women in their 30s and 40s. Age-related hepatic slowing, higher free drug fractions from reduced albumin, increased adipose tissue extending half-life, a disproportionate polypharmacy burden, and baseline orthostatic hypotension in many older adults combine to create a risk profile that is qualitatively different from the trial population.

The North American Menopause Society's 2022 position statement on sexual health in midlife and beyond does not include flibanserin among recommended options for postmenopausal women. [16]

For any clinician considering flibanserin in a patient aged 65 and older, the specific question to answer is: does this patient meet the premenopausal criterion, carry zero CYP3A4 inhibitors in her medication list, have normal hepatic function, maintain a reliable alcohol abstinence, and not use any other CNS depressant? If the answer to any part of that question is no, flibanserin is contraindicated or carries unquantified risk that the published evidence cannot support.